NewsNTech
(NASDAQ: GTBP), a clinical-stage oncology company, has integrated AI-based tools across both the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins.
The company says those efficiency gains are expected to advance multiple new development candidates through its pipeline.
Scope of the AI Deployment The integration spans two distinct stages of GT Biopharma's internal process: early-stage discovery, where candidate molecules are identified, and engineering, where those candidates are refined and optimized for development.
GT Biopharma has not specified which AI platforms it is using, nor whether the tooling is built in-house or sourced externally. The company's work is organized around two primary program categories.
Keep reading